Ribavirin is used in the treatment of chronic hepatitis C virus (HCV) infection. It is used in combination with interferon.
🛒 How to order this item?
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Show More
Consumption of alcohol is not recommended during treatment with Copeg 200mg Capsule.
Copeg 200mg Capsule is not recommended for use in pregnant women unless necessary. Discuss the risks and benefits with your doctor.
Copeg 200mg Capsule is not recommended for use in breastfeeding women unless necessary. Discuss the risks and benefits with your doctor.
Copeg 200mg Capsule has very little effect on your ability to drive or use machines.
Take Copeg 200mg Capsule with caution, especially if you have a history of Kidney diseases/conditions. The dose may be adjusted by your doctor as required.
Take Copeg 200mg Capsule with caution, especially if you have a history of Liver diseases/conditions. The dose may be adjusted by your doctor as required.
This medication is a ribonucleic analog that prevents viral RNA synthesis and viral mRNA clapping, thereby inhibiting nucleoside. In the form of purine RNA nucleotides, it affects RNA metabolism which is needed for viral replication.
Ribavirin is an antiviral medication used to treat various viral infections, including hepatitis C, respiratory syncytial virus (RSV) infections, viral hemorrhagic fever, influenza A and B, and adenovirus infections. It is specifically indicated for severe lower respiratory tract RSV infections in patients with underlying compromising conditions such as prematurity, bronchopulmonary dysplasia, chronic lung conditions, congenital heart disease, immunodeficiency, immunosuppression, and recent transplant recipients.
Ribavirin is a synthetic nucleoside that has inhibitory action against the respiratory syncytial virus, influenza virus, and herpes simplex virus. The mechanism of action is not clear. It may act at several sites including cellular enzymes to interfere with viral nucleic acid synthesis. The mono- and triphosphate derivatives are known to be responsible for the antiviral action of the compound.
The recommended duration of treatment for patients who have not been previously treated with interferon is 24 to 48 weeks. After 24 weeks of treatment, the virologic response should be assessed, and treatment discontinuation should be considered for patients who have not achieved an undetectable level of HCV RNA by that time. There are no safety and efficacy data on treatment for longer than 48 weeks in previously untreated patients.
For patients who have experienced a relapse following interferon therapy, the recommended duration of treatment is 24 weeks. There are no safety and efficacy data on treatment for longer than 24 weeks in patients who have experienced a relapse.
When using Ribavirin in combination with interferon or peg-interferon, the treatment duration and dosages depend on the HCV genotype and the patient's weight:
Ribavirin + Interferon:
Ribavirin + Peg-Interferon:
Ribavirin can be taken with or without food, but it should be taken consistently. Drinking plenty of water while on treatment with Ribavirin is recommended to reduce the risk of serious side effects. Always follow your doctor's instructions and take Copeg 200mg Capsule as directed, swallowing the whole tablet without chewing, crushing, or breaking it.
Drug-Drug Interaction: Copeg 200mg Capsule may interact with certain medications used to treat HIV/AIDS, such as stavudine, zidovudine, and didanosine. Additionally, it may interact with immunosuppressants like azathioprine.
Drug-Food Interaction: No interactions with food have been reported for Copeg 200mg Capsule.
Drug-Disease Interaction: Copeg 200mg Capsule should be avoided if you have any blood disorder or a history of a heart attack. Inform your doctor if you have conditions such as anemia, depression, severe eye disorders, dental disorders, HIV/AIDS, or heart problems before taking Copeg 200mg Capsule.
As with any medication, it is essential to inform your healthcare provider about all the medications you are taking, any medical conditions you have, and any allergies you may have to avoid potential interactions or adverse effects. Your doctor will determine the suitability of Copeg 200mg Capsule based on your individual health profile.
Ribavirin is contraindicated in pregnant women due to the potential risk of fetal harm. It should not be used by women who are pregnant or may become pregnant. If the drug is used during pregnancy or if the patient becomes pregnant while taking Ribavirin, the patient should be informed of the potential hazard to the fetus.
Additionally, Ribavirin should be used with caution in patients with hemoglobinopathies, such as thalassemia major or sickle-cell anemia. Combination therapy with Ribavirin and didanosine has been associated with reports of fatal hepatic failure, peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis in clinical trials.
As with any medication, it is crucial for healthcare providers to carefully consider the potential risks and benefits of Ribavirin treatment for each patient, taking into account their individual health conditions and medical history. Pregnant women or patients with certain pre-existing conditions may require alternative treatment options or close monitoring during Ribavirin therapy to minimize potential adverse effects.
Pregnancy Category X. Ribavirin produced significant embryocidal and/or teratogenic effects in all animal species in which adequate studies have been conducted. Malformations of the skull, palate, eye, jaw, limbs, skeleton, and gastrointestinal tract were noted. The incidence and severity of teratogenic effects increased with the escalation of the drug dose. Survival of fetuses and offspring was reduced.
Nursing Mothers: It is not known whether Ribavirin is excreted in human milk. Because many drugs are excreted in human milk and to avoid any potential for serious adverse reactions in nursing infants from ribavirin, a decision should be made either to discontinue nursing or therapy with Ribavirin, based on the importance of the therapy to the mother.
Ribavirin is associated with serious risks, particularly for pregnant women and their partners. It is essential to avoid using Ribavirin during pregnancy and for 6 months after treatment due to the potential for birth defects and fetal death. Prior to starting treatment, patients must have a negative pregnancy test, and both male and female patients must use at least two forms of contraception during treatment and for 7 months after treatment. This is to prevent pregnancy while on Ribavirin therapy.
If any severe symptoms such as stomach pain, vomiting, or nausea occur while taking Ribavirin, immediate medical attention should be sought, as these could be signs of a rare but severe side effect known as lactic acidosis.
Store below 30°C. Keep protected from light. Keep medicines out of the reach of children. Do not use later than the date of expiry.
Disclaimer:
ePharma sole intention is to ensure that its consumers get proper
information as musch as possible. Although we do not guarantee the
accuracy and the completeness of the information that provided and
here information is for informational purposes only.
The information contained herein should NOT be used as a substitute
for the advice of a qualified physician. This may not cover
everything about particular health conditions,
lab tests, medicines, all possible side effects, drug interactions,
warnings, alerts, etc. Please consult your healthcare professional
and discuss all your queries related to any disease or medicine. We
intend to support, not replace, the doctor-patient relationship.